← Full daily brief

Mass Tort brief

Financial Windfalls and Toxic Torts

Israeli courts advance landmark bank and insurer class actions as industrial polluters face new civil liabilities.

Signalpoint TeamBrief

Mass Tort

The court certified a ₪15 billion mass tort against Israel's largest banks — challenging the multi-billion windfall lenders pocketed by denying depositors checking interest.

BackgroundClass-action certifications in Israel require plaintiffs to show a reasonable possibility that contested commercial practices violated fair trading laws. When the Bank of Israel pushed borrowing rates to 4.75%, commercial lenders deposited client funds at the central bank while paying depositors zero.

Points
  1. The court certified the class action covering customers holding positive balances from April 2022 to May 2025, creating unprecedented financial liability for banks.
  2. Bank Leumi carries an estimated ₪6 billion in exposure, with Mizrahi-Tefahot, Discount Bank, and FIBI bearing proportionate shares of the claim.
  3. Plaintiffs demonstrated banks captured a spread of roughly 4.3 percentage points, arguing lenders profited from unjust enrichment under domestic consumer laws.

Mass Tort

Five major insurers settled claims of withholding interest on late payouts — agreeing to hundreds of millions in refunds while routing 30% to IDF reservists.

BackgroundUnder Section 28(a) of Israel's Insurance Contract Law, insurers must attach legal interest to claim benefits if payment is not remitted within 30 days of submission. Consumer advocacy suits alleged major carriers systematically omitted this statutory interest when distributing delayed payouts.

Points
  1. Migdal, The Phoenix, Clal Insurance, Harel, and Ayalon will deposit hundreds of millions of shekels into a supervised fund within 45 days of final court sign-off.
  2. In an unprecedented public-interest clause reflecting wartime conditions, 30% of settlement funds will be transferred to an official fund aiding IDF reservists.
  3. The remaining settlement cash will be distributed directly into verified bank accounts of policyholders whose payments were delayed beyond statutory limits.

Mass Tort

Ashdod residents launched an environmental mass tort against the local oil refinery — demanding damages and production shutdowns over illegal emissions of carcinogenic benzene.

BackgroundIndustrial facilities operating near populated coastal hubs in Israel are subject to stringent Clean Air Law emission thresholds enforced by the environmental ministry. Repeated violations of airborne chemical ceilings can expose plant operators to civil mass torts from adjacent communities.

Points
  1. An expert environmental study filed with the court documented chronic benzene spikes affecting residential neighborhoods and the Northern Industrial Zone.
  2. The petition seeks financial damages for health impairments alongside an immediate court injunction forcing the refinery to halt non-compliant refining units.
  3. The case establishes a major legal precedent for toxic mass torts in Israel, challenging state environmental compliance enforcement over heavy industrial refineries.

Mass Tort

Teva's price-fixing settlements entered the consumer payout phase — bringing closure to a multi-year antitrust mass tort that weighed on the drugmaker's valuation.

BackgroundState attorneys general initiated nationwide antitrust and price-fixing litigation against generic pharmaceutical manufacturers for allegedly conspiring to inflate prices across dozens of medications. Dual-listed Teva has spent years establishing settlement reserves to resolve legacy generic pricing and opioid claims.

Points
  1. California Attorney General Rob Bonta urged affected consumers to submit claims for compensation over inflated costs across more than 80 generic drugs.
  2. Teva continues to navigate consolidated product liability claims under federal multi-district litigation in Connecticut alongside ongoing opioid payouts.
  3. Resolving these mass-tort payouts frees up operating cash flow for the Tel Aviv-based pharmaceutical giant to invest in innovative drug pipelines.

Mass Tort

Unlock the full brief

Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.

Or read free in the appDownload on the App Store